Mining the post-mortem human brain for neurodegenerative marker: high throughput deep sequencing of cell type specific transcriptomes

May 10, 2018

This webinar will highlight the use of high-throughput sequencing of post-mortem human brain tissue to identify neurodegenerative markers and identify potential drug targets.

Dr. Steve Sheardown, Head of Molecular Biology and Cell Engineering at pharmaceutical company Cerevance, will discuss a technology platform called NETSseq (Nuclear Enriched Transcript Sort sequencing). Cerevance uses NETSseq to interrogate the molecular diversity of individual neuronal cell types in human tissue to understand their genetic complexity, the contribution that each of these make to circuit function, and, in the context of brain disorders, their potential for therapeutic intervention.

Cerevance is building an extensive collection of transcriptomes from cell types selected for relevance to human disease covering both sexes and spanning different ages from donor samples obtained from diseased populations. Since commencing clinical data collection in October 2017, Cerevance have already accumulated over 1,300 high quality individual transcriptomes. Using this unique resource, the company aims to identify and pursue novel drug targets to address areas of high unmet medical need within the field of central nervous system disorders.

Dr. Sheardown will discuss how his team has transformed NETSseq from a low-throughput proof of concept to a robust high-throughput process for generating deep sequencing libraries from limited quantities of fixed post-mortem tissue. To achieve this, Cerevance has rigorously tested a range of products at every stage of the process, focusing on yield, quality, reproducibility, and automatability.

Drawing on examples from the company's transcriptome dataset, Dr. Sheardown will illustrate the depth of information that his team can generate using its NETSseq platform.

Click here to register.

Location: GenomeWeb Webinar
When: 10 May 2018 - 9:00AM

Steve Sheardown, PhD

Head of Molecular Biology and Cell Engineering, Cerevance

X
Steve Sheardown, PhD

Head of Molecular Biology and Cell Engineering, Cerevance

Dr. Steve Sheardown received his BSc in Genetics from University of Sheffield and his PhD in Somatic Cell Genetics and Developmental Biology from Edinburgh University. He went on to undertake postdoctoral research at the MRC Embryology and Teratology Unit using the then novel mouse knockout technology to generate models of human disease, and then the MRC Clinical Sciences Centre where he studied developmental regulation of the mouse Xist gene. From there he moved on to GSK as a founding member of the Transgenic Technologies Group, followed by taking a position with Takeda Cambridge as Transgenics Group Head. Dr. Sheardown joined Cerevance in 2016 to head up Molecular Biology and Transgenics, with the goal of transforming NETSseq into a high throughput CNS drug discovery platform.

Ashesh Saraiya, PhD

Product Manager, NuGEN Technologies, Inc.

X
Ashesh Saraiya, PhD

Product Manager, NuGEN Technologies, Inc.

Dr. Ashesh Saraiya received his PhD in Molecular Biology from Wayne State University, followed by a postdoctoral position at the University of California, San Francisco where he discovered a novel microRNA precursor in the protozoan parasite Giardia lamblia. Dr. Saraiya joined NuGEN in 2013 as part of the Technical Support Team and then moved to his current role in product management.